Pharmaceutical Technology2h
Semaglutide shortage ends as FDA sets deadline for compounders
With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions are no longer allowed – for now.
pharmaphorum3h
Compounders cast adrift after semaglutide shortage ends
The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales ...
Domino's Pizza earnings on tap; Zoom, Hims and Hers after the close
Domino's Pizza -- one of the best performing stocks of the last two decades -- headlines Monday's slate of earnings. Hims & Hers Health -- [whose shares tumbled Friday after Novo Nordisk said a shorta ...
Hosted on MSN6h
Hims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide Update
Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug ...